NCT00437086View on ClinicalTrials.gov

Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions

Chronic Myeloproliferative DisordersLeukemia

Interventions

DRUG

PS-341

1.6 mg/m2 by IV; 4 out of 5 weeks

Trial Locations (3)

32224

Mayo Clinic in Florida, Jacksonville

55905

Mayo Clinic, Rochester

77030-4009

M. D. Anderson Cancer Center at University of Texas, Houston

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER